Curtiss-Wright heads into the second half of 2026 with options traders hedging more than usual, insiders selling at the top, and the next earnings print eight weeks out — a combination worth watching closely.
The clearest signal this week is in options. Demand for downside protection has risen to near its highest level of the past year, with the put/call ratio at 1.33 against a 20-day average of 1.19. That puts the reading roughly one standard deviation above the norm, and just below the 52-week high of 1.38 reached earlier this month. The shift has been rapid: through mid-May the PCR was running below 1.00, meaning call-buying dominated. Since then, puts have taken a steady lead, and the ratio has held above 1.20 for most of June. That's a meaningful rotation toward protection on a stock that had been quietly trending higher.
The lending market tells a completely different story. Borrow availability is extraordinarily loose — there are more than 57 shares available to borrow for every one currently shorted, near the top end of the year's range. Short interest itself has drifted sideways at just over 2% of the free float, with this week's reading essentially flat versus a month ago despite a 20% rise in absolute shares short over thirty days. The cost to borrow remains trivial at 0.47%. This is not a short-seller-driven setup; bears aren't piling in, and there is no squeeze pressure to speak of. Positioning looks cautious through options, not crowded through short interest.
The insider activity is harder to dismiss. CEO Lynn Bamford sold 5,000 shares across two transactions in early June, raising roughly $3.7 million at prices between $722 and $758. That follows another $2.2 million in CEO sales back in March. Over the past 90 days, net insider selling across all CW executives has totalled more than $9.2 million — a consistent one-way flow at or near the stock's all-time highs. CFO K. Christopher Farkas also sold in March. The trades carry low significance scores individually, and scheduled selling plans are common, but the pattern across multiple executives at elevated prices adds a layer of context that is hard to ignore entirely.
On the Street, the picture is broadly constructive but not aggressively so. Citigroup's John Godyn raised his target to $793 from $775 this morning, maintaining a Neutral rating — his fourth consecutive target raise since initiating coverage in December 2025. Stifel holds a Hold at $723. The consensus target of $791 sits roughly 4% above Tuesday's close of $757.76, implying modest upside rather than a compelling re-rating case. The bull argument centres on Defence Electronics momentum — 17.5% revenue growth, raised full-year guidance of 10–11%, and strong free cash flow conversion. Bears point to order timing risk, with $50 million in orders already pushed out of Q3 2025 due to continuing resolution uncertainty, and to valuation: at roughly 47x trailing earnings and 32x EV/EBITDA, the stock prices in a great deal of execution. The ORTEX short score of 32 is unremarkable, and the dividend score ranks in the 99th percentile — reflecting a shareholder-returns-focused management team, though the dividend yield itself is negligible at the current price.
Peer performance over the past week adds some texture. BWXT, the closest correlated name, fell 7.3% — a notably worse week than CW's modest 1% pullback. AIR and DCO bucked the trend, rising 8% and 14% respectively. The dispersion across the group suggests stock-specific catalysts rather than a sector-wide move, which puts more weight on CW's own Q2 print on August 5 as the next real test of whether the raised guidance holds.
Q2 results on August 5 will show whether Defence Electronics can sustain the growth rate that has underpinned the last several quarters of target increases — and whether the order timing delays that clouded 2025 have cleared.
See the live data behind this article on ORTEX.
Open CW on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
